Skip to content
Life Sciences Series B Founded 2019

SalioGen Therapeutics

Provider of gene editing platform for cell and gene therapies for inherited diseases. The company offers the proprietary Exact DNA Integration Technology (EDIT) platform, which is a genome engineering technology that is mammal-derived, for use non-viral gene therapy for patients suffering from inherited diseases and genetic diseases like Familial hypercholesterolemia, and Inherited macular degeneration. The company…

📍 United States · Rare Diseases,

Funding snapshot

Last roundSeries B
Amount$132M
Date24 November 2021
Total raised$152M
Team size50

About

Provider of gene editing platform for cell and gene therapies for inherited diseases. The company offers the proprietary Exact DNA Integration Technology (EDIT) platform, which is a genome engineering technology that is mammal-derived, for use non-viral gene therapy for patients suffering from inherited diseases and genetic diseases like Familial hypercholesterolemia, and Inherited macular degeneration. The company was founded in 2019 and headquartered in United States. It has raised $152.2M in series b funding, with backing from PBM Capital, GordonMD Global Investments, EPIQ, Fidelity Investments, and others. The company operates in the Life Sciences - Rare Diseases, Life Sciences - Gene Therapy, Life Sciences - Genomics space. Its offerings span Rare Diseases - Drugs - Diversified.

Business model

Rare Diseases > Drugs > Diversified,

Genomics > Enabling Technologies > Technology Platforms > Gene Editing

Institutional investors

PBM Capital GordonMD Global Investments EPIQ Fidelity Investments T. Rowe Price Cystic Fibrosis Foundation Symbiosis International University RD Fund D1 Capital Partners SymBiosis

Latest coverage

No articles yet.

Raising like SalioGen Therapeutics?

Analyze your pitch deck before your next raise.

Analyze My Deck →